Dose tailoring of dabigatran etexilate: obvious or excessive?

Bibliography

• Powell JR. Are new oral anticoagulant dosing recommendations optimal for all patients? JAMA 2015;313(10):1013–14
   PubMed Web of Science ®Google Scholar
• Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther 2014;39(6):628–36
   PubMed Web of Science ®Google Scholar
• Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171(14):1285–6
   PubMed Web of Science ®Google Scholar
• McConeghy KW, Bress A, Qato DM, et al. Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy 2014;34(6):561–9
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. Eng J Med 2013;368(14):1272–4
   PubMed Web of Science ®Google Scholar
• Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Int Med 2015;175(1):18–24
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015;4(4):pii: e001798
   Google Scholar
• Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014;167(3):329–34
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163(1):13–19; e1
   PubMed Web of Science ®Google Scholar
• Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011;162(4):606–12; e1
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Pradaxa - Full Prescribing Information. 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf [Cited 01 April 2015]
   Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15 Suppl 1:9S–16S
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Pradaxa - Clinical Pharmacology and Biopharmaceutics Review(s). 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR.pdf [Cited 01 April 2015]
   Google Scholar
• Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now!. Thromb J 2013;11(1):8
   PubMedGoogle Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63(4):321–8
   PubMed Web of Science ®Google Scholar
• Chan NC, Coppens M, Hirsh J, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2015;13(3):353–9
   PubMed Web of Science ®Google Scholar
• Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127(13):1404–12
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Pradaxa - Summary of Product Characteristics. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf [Cited 01 April 2015]
   Google Scholar
• European Medicines Agency. Pradaxa - EMEA/H/C/000829/X/13/G. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf [Cited 01 April 2015]
   Google Scholar
• Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11(4):756–60
   Google Scholar
• Baglin T, Keeling D, Kitchen S; British Committee for Standards in H. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159(4):427–9
   PubMed Web of Science ®Google Scholar
• Douxfils J, Mani H, Minet V, et al. Non-vka oral anticoagulants: accurate measurement of plasma drug concentrations. Biomed Res Int 2014
   Google Scholar
• Hapgood G, Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013;110(2):308–15
   PubMed Web of Science ®Google Scholar
• Douxfils J, Dogne JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110(3):543–9
   PubMed Web of Science ®Google Scholar
• Douxfils J, Lessire S, Dincq AS, et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015;113(4):862–9
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625–51
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. An Idea for a Mid to Long Term Strategy for Pradaxa, showing EMA range comparisons. 2014. Available from: http://journals.bmj.com/site/bmj/dabigatran/compared_ema.pdf [Cited 01 April 2014]
   Google Scholar
• Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010;8(4):627–30
   PubMed Web of Science ®Google Scholar
• Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010;8(4):621–6
   PubMed Web of Science ®Google Scholar
• Rao RB. Regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol 2014;63(25 Pt A):2885
   PubMed Web of Science ®Google Scholar
• Douxfils J, Chatelain B, Dogne JM, Mullier F. Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. J Thromb Haemost 2015; 10.1111/jth.12880. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 10.1016/S0140-6736(14)61943-7. [Epub ahead of print]
   Web of Science ®Google Scholar
• Food and Drug Administration. Eliquis - Clinical Pharmacology and Biopharmaceutics Review(s). 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf [Cited 05 May 2015]
   Google Scholar
• Food and Drug Administration. Xarelto - Clinical Pharmacology and Biopharmaceutics Review(s). 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf [Cited 18 April 2015]
   Google Scholar